Abbildung 59: EUROPA-Studie - Benefit
Once again, the absolute benefits were achieved with perindopril 8 mg once daily in the EUROPA trial: "Adding perindopril to standard optimal therapy over a four year period would stop 50,000 heart attacks or cardiovascular deaths in a country with a population of 60 million" concluded prof. Kim Fox, the study chairman. "The EUROPA trial provides clear evidence of major health gains for these patients. If the findings are applied worldwide then many millions of lives could be saved" added prof. Willem Remme, the study chairman.